Although future mechanistic studies need to be performed to fully delineate the role of ERK5 and BRD4 in the onset of non-proliferative diabetic retinopathy, it is notable that this study identified a potentially novel therapeutic that could ablate diabetes-mediated retinal pathogenesis and vascular impairment. Here, MAPK7 is linked to proliferative diabetic retinopathy.